Celldex Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Celldex Therapeutics, Inc. (CLDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $25.09 per share for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-11-06
- Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-09-30 was $25.09, a 2.75% decline year-over-year.
- Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-06-30 was $26.41, a 6.74% decline year-over-year.
- Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $28.64, a 13.86% decline year-over-year.
- Celldex Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-09-30 was $25.80, a 1.65% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2024-09-30 | $25.09 10-Q · filed 2024-11-06 | $26.36 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $26.41 10-Q · filed 2024-08-08 | $26.42 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $28.64 10-Q · filed 2024-05-06 | ||
| 2023-09-30 | $25.80 10-Q · filed 2023-11-02 | $28.38 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $28.32 10-Q · filed 2023-08-08 | $28.41 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $33.25 10-Q · filed 2023-05-04 | ||
| 2022-09-30 | $25.38 10-Q · filed 2022-11-09 | $17.36 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $17.20 10-Q · filed 2022-08-08 | $17.29 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $24.63 10-Q · filed 2022-05-05 | ||
| 2021-09-30 | $41.34 10-Q · filed 2021-11-09 | $21.86 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $21.73 10-Q · filed 2021-08-05 | $21.71 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $15.20 10-Q · filed 2021-05-06 | ||
| 2020-09-30 | $9.25 10-Q · filed 2020-11-05 | $7.99 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $7.96 10-Q · filed 2020-08-06 | $7.95 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $1.23 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |